Navigation Links
Chronic disease management: Does it improve health and save money?
Date:5/12/2008

INDIANAPOLIS A study published in the May/June issue of Health Affairs reports on the first randomized trial providing a scientifically valid look at what one might expect from chronic disease management programs that serve low-income individuals. The study result provides good news for state Medicaid leaders struggling to meet the needs of individuals with chronic conditions and also suggests that some disease management efforts, even among relatively low-risk patients, may be an effective strategy.

While chronic disease management programs, also known as chronic care management, have become widespread across the United States, gaining favor with employer groups, health-care organizations and health payers, these programs are being increasingly questioned because very little scientific evidence exists regarding their effectiveness and fiscal impact.

Researchers from the Indiana University School of Medicine, the Regenstrief Institute, and the School of Public and Environmental Affairs at Indiana UniversityPurdue University Indianapolis designed a study to determine whether chronic disease management of individuals with diabetes and/or congestive heart failure (CHF) improves health outcome and lowers healthcare costs.

In contrast to earlier studies, the researchers randomly assigned individuals with the two chronic conditions to either chronic disease management or a control group based on their primary care providers location. The researchers used a predictive model to identify individuals at risk for high levels of future health-care utilization. Individuals judged to be at highest risk were given intensive health care management conducted by a nurse care manager. Those with lower risk were provided with education and care support over the phone. Their findings were much more complex than they had anticipated.

The telephonic support, when given to the lower risk group for either disease, resulted in a significant reduc
'/>"/>

Contact: Cindy Fox Aisen
caisen@iupui.edu
317-274-7722
Indiana University
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Risks for painkiller abuse do not outweigh benefits in chronic pain
2. Patients with chronic illness benefit from telehealth intervention
3. New Book Helps Older Adults Manage Chronic Pain
4. New treatment could reduce chronic lung disease in premature babies
5. Mix of 2 pain-relief procedures can end chronic back and leg pain without drugs
6. Health Woes Not Always to Blame for Chronic Cough
7. Chronic Exposure to Solvents Disturbs Brains Wiring
8. Overuse of Opioids, Barbiturates Boosts Chronic Migraine Risk
9. New Jersey Leaders Join Forces to Battle Chronic Disease
10. Disturbances in brain circuitry linked to chronic exposure to solvents
11. Potential blood test for chronic sinusitis identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...r University Medical Center at Dallas and the Bayl...introduce insulin genes into the pancreas//. Ins... sugar) to enter the cells of the body to be used ...ltrasound-targeted micro bubble destruction (UTMD)...
...uota issue between government and striking medicos...ing with their demand of setting up an experts com...riking medicos are also expected to meet Union Hea...r in the day. The resident doctors association of...
...ug Administration authority is under pressure as i...rug as an over-the counter drug//. Andrew von Esc...rged to take an independent, non-biased decision o...d to sell its morning after pill or Plan B without...
...ior doctors of Sir Sunderlal hospital in the Banar...unger strike// for the second consecutive day toda...a for the backward castes in the higher education ...nger strike, the agitating doctors formed human ch...
Other Medicine News:Health News:Bubble Technique on the cards For Treatment of Type I diabetes 2
(Date:10/6/2008)... Annual Scientific Conference -, ORLANDO, Fla., O...rmerly Microbia) today announced presentation of d... the role that cyclic guanosine,monophosphate (cGM...dies,demonstrate that cGMP inhibits intestinal pai...a and desensitizes colonic afferent nerves in a,si...
(Date:10/6/2008)...MICADE Therapy is More Likely to Induce Steroid-...tandard Immunomodulator, Azath...ta presented for the first time,from the Phase 3b ...munomodulators and Biologic Therapy (SONIC) may pr...tients with moderate to severe Crohn,s disease.,Ac...
(Date:10/6/2008)...eristics of Naltrexone SR Associated with ...PHOENIX, Oct. 6 /- Orexigen...eutical company focused on the treatment of,obesit...rs, today presented,data showing the investigation...), successfully achieved key objectives (lowered n...
(Date:10/5/2008)...nd Journal of Medicine reaffirm,well-established e...,HandiHaler(R), RIDGEFIELD, Conn., and NEW YORK, ...rstanding Potential Long-term Impacts on Function ...diHaler(R) (tiotropium bromide,inhalation powder),... 4,years as measured by FEV(1) (p<0.001) versus pl...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Argosy publishing launches The Visible Body 13442 1Argosy publishing launches The Visible Body 13442 2Argosy publishing launches The Visible Body 13442 3Sleep Medicine Associates Opens New Doors at Swedish Cherry Hill Campus 13437 1Sleep Medicine Associates Opens New Doors at Swedish Cherry Hill Campus 13437 2Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 1Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 2Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 3Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 4Diamonds Retirement Study Finds Companies Ill Prepared to Meet Baby Boomers Health and Wealth Needs 13434 5New potential drug target for the treatment of atherosclerosis 13430 1New potential drug target for the treatment of atherosclerosis 13430 2New potential drug target for the treatment of atherosclerosis 13430 3
... -- Genotypically Optimized Dosing Results in Impr... -- , MELBOURNE, Australia, and MENLO PARK, Califo...s (ASX: CXS, NASDAQ: CXSP) announced,today the pre...ydrochloride) phase 1/2a dose-escalation study, de...of Quinamed in heavily,pre-treated patients with a...
... Data From the Companies, Novel Heat Shock Protein...olerability, and Biological,Activity , CAMBRIDGE, ...EWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq...ounced updated interim,results from a Phase I clin... (Hsp90) inhibitor, IPI-504, in patients with rela...
Other Medicine Technology:ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 2ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 3ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 4Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 2Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 3Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 4Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 5Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 6Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 7
...tem will define the state of knee implants. Now, f... requirements and increasing surgical options, whi...ons. The GENESIS II femoral components meet these...tomeet todays surgical demands. Clinical issues su...
Cruciate retaining, posterior stabilized and constrained components.
...tmental total knee prosthesis stems from many year...he-art design and manufacturing technologies have ...l function as well as a favorable pressure distrib... keep wear to a minimum. The inherent design of th...
Offset Liners - Plus 5 mm Neutral
Medicine Products: